We are live on ! Find out more
NVS icon

Novartis

937 hedge funds and large institutions have $22.2B invested in Novartis in 2017 Q3 according to their latest regulatory filings, with 70 funds opening new positions, 348 increasing their positions, 336 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more call options, than puts

Call options by funds: $41.3M | Put options by funds: $22.2M

59% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 44

2% more funds holding

Funds holding: 920937 (+17)

4% more repeat investments, than reductions

Existing positions increased: 348 | Existing positions reduced: 336

2% more capital invested

Capital invested by funds: $21.7B → $22.2B (+$474M)

0.06% less ownership

Funds ownership: 11.09%11.03% (-0.06%)

5% less funds holding in top 10

Funds holding in top 10: 4038 (-2)

Holders
937
Holders Change
+17
Holders Change %
+1.85%
% of All Funds
23.36%
Holding in Top 10
38
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-5%
% of All Funds
0.95%
New
70
Increased
348
Reduced
336
Closed
44
Calls
$41.3M
Puts
$22.2M
Net Calls
+$19.2M
Net Calls Change
-$5M
Name Holding Trade Value Shares
Change
Change in
Stake
KLI
551
Kelman-Lazarov Inc
Tennessee
$646K
FWCM
552
Ferguson Wellman Capital Management
Oregon
$643K
ACM
553
Advent Capital Management
New York
$634K +$622K +8,242 New
NAM
554
NTV Asset Management
West Virginia
$632K -$28.3K -375 -4%
MA
555
Montag & Associates
Georgia
$622K +$3.32K +44 +0.5%
RC
556
Roundview Capital
New Jersey
$621K -$5.06K -67 -0.8%
GC
557
Garde Capital
Washington
$618K +$607K +8,035 New
DJSG
558
D.J. St. Germain
Massachusetts
$617K +$8.99K +119 +2%
EAM
559
Eagle Asset Management
Florida
$613K +$599K +7,927 New
LPIC
560
LeJeune Puetz Investment Counsel
Michigan
$610K
AL
561
Aspiriant LLC
California
$606K -$281K -3,719 -32%
PCM
562
Prelude Capital Management
New York
$605K +$587K +7,777 +8,641%
Aberdeen Group
563
Aberdeen Group
United Kingdom
$601K +$590K +7,812 New
DC
564
Davenport & Co
Virginia
$593K +$5.44K +72 +0.9%
SFSIG
565
San Francisco Sentry Investment Group
California
$593K +$76.2K +1,009 +15%
PC
566
Palo Capital
California
$587K -$14.7K -195 -2%
YP
567
Yellowstone Partners
Idaho
$584K +$573K +7,587 New
RWP
568
RWA Wealth Partners
Massachusetts
$583K +$572K +7,579 New
BCM
569
Bluefin Capital Management
New York
$581K +$570K +7,549 New
1SB
570
1ST Source Bank
Indiana
$579K -$2.72K -36 -0.5%
BBA
571
BLB&B Advisors
Pennsylvania
$569K +$114K +1,507 +26%
SIC
572
Shoker Investment Counsel
Ohio
$567K -$106K -1,408 -16%
WJA
573
Williams Jones & Associates
New York
$561K +$8.38K +111 +2%
FCCM
574
First City Capital Management
Georgia
$559K
BP
575
Ballentine Partners
Massachusetts
$557K -$20.5K -271 -4%

NVS Hedge Fund Activity: Q3 2017 in Review

937 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2017, worth a combined $22.2B — up 2.2% from $21.7B a quarter earlier.

Buyers outnumbered sellers: 70 funds opened new NVS positions and 44 closed out — a net gain of 26 holders — while 348 added to existing stakes and 336 trimmed.

The largest buyer was Bank of America, adding an estimated $158M. The largest seller was Dodge & Cox, cutting an estimated $464M.

  • 937 institutional investors held Novartis (NVS) as of Q3 2017, up from 920 in Q2 2017.
  • Funds reported $22.2B of Novartis stock for Q3 2017, up 2.2% quarter-over-quarter.
  • 70 funds opened new Novartis positions in Q3 2017 and 44 closed out, a net change of +26 holders.
  • The largest Novartis buyer in Q3 2017 was Bank of America, an estimated $158M added.
  • The largest Novartis seller in Q3 2017 was Dodge & Cox, an estimated $464M sold.

Based on aggregated 13F filings for Q3 2017.